May 29. 2012 — Viatronix Inc., developer of 2-D/3-D medical imaging and diagnostic software, announced that its V3D-Colon platform was exclusively used to perform a key study recently published in the Annals of Internal Medicine. The purpose of the study was to determine the feasibility of a laxative-free bowel prep for patients undergoing a virtual colonoscopy (VC) screening exam. The trial utilized a modified version of the Viatronix V3D-Colon software.
"The trial performed by the research group led by Dr. Michael Zalis at Massachusetts General Hospital demonstrates an option for a laxative-free bowel prep and was visualized on the Viatronix V3D-Colon platform," said Zaffar Hayat, CEO and president of Viatronix Inc. "Computed tomography colonography (CTC), also known as virtual colonoscopy (VC), has been clinically proven over the past decade in multiple trials and is being adopted worldwide as a reliable alternative for colorectal cancer screening. Viatronix has been at the forefront of CTC research for many years and welcomes the scientific progress resulting from this study."
VC is now being reimbursed by insurance carriers in approximately 30 states within the United States. Both the U.S. House of Representatives and Senate have introduced legislation that will require coverage of VC as a colon cancer screening benefit under Medicare. Adding CTC to the list of approved screening services will increase compliance with screening guidelines and has the potential to reduce unnecessary deaths from colon cancer.
For more information: www.viatronix.com
April 20, 2026 
